



Gamida Cell Added to NASDAQ Biotechnology Index

December 18, 2020

BOSTON--(BUSINESS WIRE)--Dec. 18, 2020-- Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NASDAQ Biotechnology Index is re-ranked annually. All securities in the index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market and meet minimum market value and share volume requirements, among other criteria.

The NASDAQ Biotechnology Index forms the basis for a number of Exchange Traded Funds (ETFs), including the iShares NASDAQ Biotechnology ETF (Nasdaq: IBB). More information about the Index can be found at <https://indexes.nasdaqomx.com/Index/Overview/NBI>.

About Gamida Cell

Gamida Cell is an advanced cell therapy company committed to cures for patients with blood cancers and serious blood diseases. We harness our cell expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need. For additional information, please visit www.gamida-cell.com or follow Gamida Cell on [LinkedIn](#) or Twitter at [@GamidaCellTx](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20201218005103/en/): <https://www.businesswire.com/news/home/20201218005103/en/>

For investors:

Stephanie Ascher
Stern Investor Relations, Inc.
stephanie.ascher@sternir.com
1-212-362-1200

For media:

Matthew Corcoran
Ten Bridge Communications
mcorcoran@tenbridgecommunications.com
1-617-866-7350

Source: Gamida Cell Ltd.